Sellas Life Sciences (SLS +45.4%) skyrockets as much as 70% after unveiling positive results for its Phase 1/2 study of its Galinpepimut-S treatment for patients with acute myeloid leukemia.
Sellas says the trial data showed a significant
difference in the survival rate of patients treated with GPS compared
with standard care.
“We’re extremely pleased with this follow-up data,
which show that GPS may have potential as a longer-term therapy for AML
patients in CR2, an aggressive disease where the majority of patients
typically relapse and have a survival rate of approximately five months
with best standard therapy,” the company says.
https://seekingalpha.com/news/3545877-sellas-life-sciences-soars-nearly-50-on-leukemia-drug-trial-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.